However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in ...

Omeros is putting up its monoclonal antibody up for FDA approval—again. | Omeros is putting up its monoclonal antibody up for ...

KdT Ventures has signed off on a $608 million biobucks dea l for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction ...

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 ...

The FDA is elevating a recall from Boston Scientific covering its cryoablation balloon catheters for the treatment of atrial ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein.

After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a ...

The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing a lack of evidence. | The FDA has denied Zealand Pharma ...

Freshly public BioAge Labs has secured a multiyear partnership with Novartis that focuses on age-related diseases and ...